BirchBioMed Inc.

expected

Not yet set

status

Filed with SEC

Industry

Pharmaceutical Preparations

Headquarters

Canada

Incorporated in

Canada

Overview

— AI-generated from the filing, see note below

Business overview

BirchBioMed Inc. is a clinical stage biopharmaceutical company focused on developing treatments for scarring, autoimmune diseases, and organ fibrosis. The company holds exclusive licenses from the University of British Columbia for two innovative technologies, FS1/FS2 and AI-001. These technologies are designed to address serious conditions that currently lack effective solutions, including the treatment of burns and organ fibrosis. BirchBioMed aims to develop FS2 as an Rx drug for these diseases and is also working on AI-001 for conditions like type 1 diabetes and alopecia areata.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

Exclusive worldwide licenses for innovative biopharmaceutical technologies
Focus on high unmet medical needs with significant potential for breakthroughs
Completed successful Phase 1 trials showing safety of FS2 in humans
Strong partnerships with Canadian research funding bodies

Risk factors

Potential litigation affecting business operations and financial condition
Volatility in the trading price of common shares and risk of not developing a liquid market for the shares
Failure to meet Nasdaq listing requirements which could lead to delisting
Increased operational costs and management demands due to regulatory compliance as a public company
Challenges and costs associated with maintaining effective internal controls over financial reporting

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

BirchBioMed Inc. is headquartered in Canada. It is classified under Pharmaceutical Preparations.

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with BirchBioMed Inc..

Biotech IPOs Canada IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/birchbiomed" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="BirchBioMed Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/birchbiomed?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/birchbiomed/opengraph-image

Attribution text

BirchBioMed Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/birchbiomed?utm_source=embed&utm_medium=text&utm_campaign=birchbiomed

Track this IPO

Get emailed when BirchBioMed Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Oct 9, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.